Delivery Order SPE2DB24D2013-SPE2DB24FCGSY
- Not listed
- This federal contract award, valued at $5,621.59, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a wholly-owned subsidiary of Cencora, Inc. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) that Cencora, Inc. holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The contract is for the delivery of REXULTI 2 MG TABLET 30S, a pharmaceutical product, to support military...
- This federal contract award, valued at $9,608.51, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product. The award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Cencora, Inc. holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2026. This IDC serves as the...
- This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $13,888.80 firm fixed-price delivery order is for the supply of REXULTI 3 MG TABLET 30S, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop Support Medical. This single-award IDC serves as the primary...
- This federal contract award, with the ID SPE2DX15D2003|SPE2DX24F4ZZ2, was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $6,562.40 firm fixed-price delivery order is for the supply of REXULTI 1 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of January 11, 2024 and was awarded on January 10, 2024 without any set-aside designation. Amerisourcebergen Drug Corp holds a...
- This federal contract award, with ID SPE2DX15D3017|SPE2DX24F0KHF, was issued by the U.S. Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $24,295.54 Firm Fixed Price Delivery Order is for the supply of REXULTI 1 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of January 30, 2024 and was awarded on January 29, 2024. This award is not designated under any set-aside program. Amerisourcebergen...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $4,401.81 firm-fixed-price delivery order is for the supply of REXULTI 1 MG TABLET 30S, a pharmaceutical product, to support military healthcare programs. The award is not designated under any set-aside program, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award, valued at $20,117.98, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of the pharmaceutical product REXULTI 1 MG TABLET 30S. This award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December...
- This federal contract award is for pharmaceutical and medical supplies delivered to the Defense Logistics Agency (DLA) Troop Support Medical. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $17,208.60, includes the delivery of the prescription medication Rexulti 2 mg tablets and is a firm fixed-price delivery order. The contract has no set-aside designation, indicating open competition....
- This federal contract award, valued at $26,017.85, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
- This federal contract award is for the delivery of pharmaceutical products, specifically the medication Rexulti 1 mg tablet, to the Defense Logistics Agency (DLA). The contract, valued at $4,866.53, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a Firm Fixed Price Delivery Order that runs until February 22, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB24FCGSYDelivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of pharmaceutical products and medical supplies. The award, valued at $10,287.85, is a delivery order under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, which has a ceiling value of $999,999,999 and runs through November 2026. The contract covers a wide range of medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. This delivery order is for the supply of REXULTI 2 MG TABLET 30S. The contract does not have a set-aside designation, indicating that it was awarded through full and open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 4/25/24 |